Login with Linked

Follow us on

Link Linkedin Youtube

Ryzneuta

Ryzneuta is an injection that supports white blood cell production in cancer patients undergoing chemotherapy. It helps lower the risk of infection-related complications by boosting the immune system.

Molecule Details :

  • Molecule Name :

    Efbemalenograstim Alfa-Vuxw

  • Innovator :

    EVIVE BIOTECHNOLOGY

  • Approval Date :

    16-Nov-23

  • Data Exclusivity Expiry :

    16-Nov-27

  • Market Exclusivity Expiry :

    16-Nov-35

  • Dosage Form :

    Injection

  • Strength :

    20MG/ML

  • Therapeutic Category :

    Hematopoietic Growth Factor

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA

  • 2026 :

    NA

  • 2027 :

    NA

  • 2028 :

    NA

  • 2029 :

    NA

  • 2030 :

    NA

  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?